Hypothermia as a cause of death in British Columbia, 1998-2012: a descriptive assessment

Abstract

E420 CMAJ OPEN, 3(4) definitions is challenging, with questions about the validity and existence of a condition of mild cognitive impairment rather than a set of symptoms. 6 Treatment of cognitive impairment is also contentious. In 2013, the US Preventive Services Task Force review on screening for cognitive impairment evaluated both pharmaco-logic and nonpharmacologic interventions for the treatment of cognitive impairment and found evidence on the benefit of treating cognitive impairment, including mild to moderate dementia and Alzheimer disease. However, they reported a lack of clarity on the clinical importance of this evidence. 7 Another high-quality systematic review by Tricco and col-leagues 8 evaluated the treatment of mild cognitive impairment specifically using pharmacologic treatments and concluded that the evidence did not support the use of cognitive enhanc-ers for people with mild cognitive impairment. The aim of this review is to bridge the research gap by evaluating the safety and effectiveness of the pharmacologic and nonpharma-cologic treatments available for mild cognitive impairment.